vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and Netskope Inc (NTSK). Click either name above to swap in a different company.

Netskope Inc is the larger business by last-quarter revenue ($184.2M vs $94.5M, roughly 1.9× ARDELYX, INC.). ARDELYX, INC. runs the higher net margin — -39.8% vs -246.0%, a 206.2% gap on every dollar of revenue.

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

Netskope Inc is a leading global cybersecurity firm offering SASE solutions, cloud security platforms and zero trust tools. It serves enterprise clients across North America, Europe and Asia Pacific, helping secure remote workforces, cloud apps and digital assets against evolving cyber threats.

ARDX vs NTSK — Head-to-Head

Bigger by revenue
NTSK
NTSK
1.9× larger
NTSK
$184.2M
$94.5M
ARDX
Higher net margin
ARDX
ARDX
206.2% more per $
ARDX
-39.8%
-246.0%
NTSK

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
ARDX
ARDX
NTSK
NTSK
Revenue
$94.5M
$184.2M
Net Profit
$-37.6M
$-453.1M
Gross Margin
57.9%
Operating Margin
-242.7%
Net Margin
-39.8%
-246.0%
Revenue YoY
27.5%
Net Profit YoY
-401.7%
EPS (diluted)
$-0.15
$-1.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARDX
ARDX
NTSK
NTSK
Q1 26
$94.5M
Q4 25
$125.2M
$184.2M
Q3 25
$110.3M
Q2 25
$97.7M
Q1 25
$74.1M
Q4 24
$116.1M
Q3 24
$98.2M
Q2 24
$73.2M
Net Profit
ARDX
ARDX
NTSK
NTSK
Q1 26
$-37.6M
Q4 25
$-407.0K
$-453.1M
Q3 25
$-969.0K
Q2 25
$-19.1M
Q1 25
$-41.1M
Q4 24
$4.6M
Q3 24
$-809.0K
Q2 24
$-16.5M
Gross Margin
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
91.3%
57.9%
Q3 25
96.4%
Q2 25
87.3%
Q1 25
83.4%
Q4 24
84.3%
Q3 24
84.0%
Q2 24
87.1%
Operating Margin
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
4.1%
-242.7%
Q3 25
4.2%
Q2 25
-14.7%
Q1 25
-49.0%
Q4 24
7.0%
Q3 24
2.3%
Q2 24
-18.6%
Net Margin
ARDX
ARDX
NTSK
NTSK
Q1 26
-39.8%
Q4 25
-0.3%
-246.0%
Q3 25
-0.9%
Q2 25
-19.5%
Q1 25
-55.5%
Q4 24
4.0%
Q3 24
-0.8%
Q2 24
-22.5%
EPS (diluted)
ARDX
ARDX
NTSK
NTSK
Q1 26
$-0.15
Q4 25
$-0.01
$-1.85
Q3 25
$0.00
Q2 25
$-0.08
Q1 25
$-0.17
Q4 24
$0.01
Q3 24
$0.00
Q2 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARDX
ARDX
NTSK
NTSK
Cash + ST InvestmentsLiquidity on hand
$238.1M
$1.2B
Total DebtLower is stronger
$203.5M
Stockholders' EquityBook value
$148.6M
$151.0M
Total Assets
$504.5M
$1.7B
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARDX
ARDX
NTSK
NTSK
Q1 26
$238.1M
Q4 25
$68.0M
$1.2B
Q3 25
$42.7M
Q2 25
$90.0M
Q1 25
$30.8M
Q4 24
$64.9M
Q3 24
$47.4M
Q2 24
$41.9M
Total Debt
ARDX
ARDX
NTSK
NTSK
Q1 26
$203.5M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ARDX
ARDX
NTSK
NTSK
Q1 26
$148.6M
Q4 25
$166.9M
$151.0M
Q3 25
$154.3M
Q2 25
$139.5M
Q1 25
$145.7M
Q4 24
$173.3M
Q3 24
$158.3M
Q2 24
$147.0M
Total Assets
ARDX
ARDX
NTSK
NTSK
Q1 26
$504.5M
Q4 25
$501.6M
$1.7B
Q3 25
$486.2M
Q2 25
$466.8M
Q1 25
$410.2M
Q4 24
$435.8M
Q3 24
$367.9M
Q2 24
$343.5M
Debt / Equity
ARDX
ARDX
NTSK
NTSK
Q1 26
1.37×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARDX
ARDX
NTSK
NTSK
Operating Cash FlowLast quarter
$19.9M
Free Cash FlowOCF − Capex
$10.4M
FCF MarginFCF / Revenue
5.6%
Capex IntensityCapex / Revenue
5.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
$21.0M
$19.9M
Q3 25
$365.0K
Q2 25
$-25.3M
Q1 25
$-38.5M
Q4 24
$9.8M
Q3 24
$501.0K
Q2 24
$-19.4M
Free Cash Flow
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
$20.6M
$10.4M
Q3 25
$209.0K
Q2 25
$-26.0M
Q1 25
$-38.8M
Q4 24
$9.2M
Q3 24
$364.0K
Q2 24
$-19.5M
FCF Margin
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
16.4%
5.6%
Q3 25
0.2%
Q2 25
-26.6%
Q1 25
-52.3%
Q4 24
7.9%
Q3 24
0.4%
Q2 24
-26.7%
Capex Intensity
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
0.3%
5.2%
Q3 25
0.1%
Q2 25
0.7%
Q1 25
0.4%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.2%
Cash Conversion
ARDX
ARDX
NTSK
NTSK
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
2.11×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARDX
ARDX

IBSRELA$70.1M74%
XPHOZAH$23.3M25%
Non-cash royalty revenue related to the sale of future royalties$695.0K1%
Product supply revenue$354.0K0%

NTSK
NTSK

Indirect Channels$175.2M95%
Direct End Customers$8.9M5%

Related Comparisons